CSL Behring signs nine-year plasma supply agreement with National Blood Authority

CSL Behring signed a new National Fractionation Agreement with the National Blood Authority of Australia to supply plasma-derived therapies manufactured at its Broadmeadows facility. The agreement runs from 1 January 2018 to 31 December 2026.

“CSL Behring welcomes the opportunity to continue our longstanding commitment to provide plasma-derived therapies to treat people in Australia with serious medical conditions.”newsroom.csl.com

• 1 source
• newsroom.csl.comNews Releases | CSLChristina HickieDec 11, 2017

Summarized from public sources; check the original articles before acting on it.